Since the development of systemic combination chemotherapy, postchemotherapy extirpation has been performed in selected patients mainly with locally advanced and/or initially unresectable bladder cancer, and, in very selected patients, surgical consolidation for visceral metastases has also been performed. The purpose of this article was to review and summarize the current evidence for the role of surgical consolidation in metastatic urothelial carcinoma.
INTRODUCTION
Systemic chemotherapy continues to be the mainstay in the treatment of advanced metastatic urothelial carcinoma, and, based on a randomized trial demonstrating similar survival but a favorable toxicity profile compared with the methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) regimen, the combination of gemcitabine and cisplatin has now become a standard first-line chemotherapy [1] . Although initial response rates to modern cisplatin-based combination regimens have been reported to be around 50-70%, the effects are usually transient, and most patients with a favorable response will eventually develop disease progression. So far, although second-line chemotherapy regimens have been studied, such as taxanebased systemic chemotherapy [2] [3] [4] [5] , and, in Europe, vinflunine is allowed to be used for platinum-resistant metastatic urothelial carcinoma [6, 7] , the salvage strategy has yet to be fully established.
In terms of an aggressive surgical approach, the combination of systemic chemotherapy and surgical extirpation has been performed in selected patients mainly with locally advanced and/or initially unresectable bladder cancer, and the outcomes have been reported [8] [9] [10] [11] [12] [13] [14] [15] [16] . Regarding metastasectomy to visceral organs in metastatic urothelial carcinoma patients, Cowles et al. [17] firstly reported surgical outcomes in patients with lung metastasis of urothelial carcinoma. They observed a median of 5-year survival in six patients after the removal of a solitary lung metastasis without systemic chemotherapy. Since then, surgical consolidation for visceral metastases has also been performed in selected patients, and its beneficial role was anecdotally reported [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . In the present study, we reviewed the current evidence in terms of an aggressive surgical approach to advanced urothelial carcinoma, and
INDICATION OF METASTASECTOMY FOR METASTATIC UROTHELIAL CARCINOMA
At present, there are no strict criteria regarding the indications of surgical consolidation for metastatic urothelial carcinoma, and the role of metastasectomy has not yet been examined in a randomized setting. Although each study group considered surgical consolidation based on their own guidelines, they have many things in common. In the M.D. Anderson Cancer Center group, they consider metastasectomy when the patients demonstrate a good response to systemic chemotherapy, have metastasis at the initial or a single site, have a disease which is considered resectable with a negative surgical margin, and show a stable disease without rapid progression [18] . In a German multi-institutional study, Lehmann et al. [19] stated that surgical consolidation remains investigational and should be offered when the disease is limited and shows a favorable response to systemic chemotherapy, and surgical consolidation of all detectable disease seems feasible. Our group also performed surgical consolidation in extremely selected patients, and reported the outcomes [20, 21] . Figure 1 shows actual computed tomography (CT) images in the patients undergoing surgical consolidation. We usually considered surgical consolidation in the situation whereby the disease was restricted to a single organ, the number was ideally one, and the patient had a good performance status and showed a good response to systemic chemotherapy [20] . Herr [29] also listed pivotal points regarding patient selection in his editorial comment on the study by Lehmann et al. as follows:
(1) Systemic chemotherapy first, because it works for patient selection, and the extent of surgery.
(2) Consider surgical consolidation in patients with a good response (complete or partial) to systemic chemotherapy. Regarding postchemotherapy radiological images, it is difficult to distinguish patients from those without remaining viable cancer. Although PET is promising in the postchemotherapy treatment decision regarding testicular seminoma [30] [31] [32] [33] , its role in urothelial carcinoma is investigational at present [34, 35] Regarding the salvage outcomes in patients who failed to respond to first-line chemotherapy, Otto et al [36] . reported an unfavorable prognosis in a study of 70 patients refractory to the MVAC regimen. Most patients had multiple metastases (76%, 53/70) involving multiple organs (41%, 29/70), the median survival time was 7 months, and the 1 and 2-year survival rates were 30.7 and 19.3%. In 83% of the symptomatic patients (42/51), surgery improved their performance status, whereas asymptomatic patients complained of a reduced quality of life after surgery. A perioperative mortality rate of 4% (3/70) was also observed. On the basis of these observations, they concluded that metastasectomy for disease refractory to systemic chemotherapy had an impact on the quality of life of symptomatic patients only, and offered no survival advantage.
Taken together with these opinions, surgical consolidation should be currently considered in patients with a good response to systemic chemotherapy, stable disease after chemotherapy, oligometastasis ideally limited to a single site, a good health status, and a strong motivation for aggressive treatment. In the following paragraphs, we reviewed the specific treatment outcomes according to metastatic sites.
POSTCHEMOTHERAPY SURGERY IN PATIENTS WITH INITIALLY UNRESECTABLE OR NODE-POSITIVE BLADDER CANCER
A rationale of postchemotherapy surgery is the high likelihood of relapse at the initial disease sites.
KEY POINTS
The role of metastasectomy has not yet been examined in a randomized setting.
Each study group has offered surgical consolidation to metastatic urothelial carcinoma patients according to their own guidelines, and there are many things in common, such as a good response to systemic chemotherapy, limited disease, the feasibility of resection, and a favorable performance status. Careful patient selection is mandatory.
Regarding metastasectomy for visceral metastasis, recent evidence suggested that lung metastases (ideally a small solitary lesion) would be a good indication.
Dimopoulos et al. [37] previously reported the relapse pattern and its outcome in the analysis of 58 patients who developed relapse after a complete response (CR) or partial response (PR) induced by cisplatin-based systemic chemotherapy. The median interval from the maximum effect of chemotherapy to disease relapse was about 9 months (range 3-53), and, of the patients who initially presented with locoregional disease (n ¼ 42), 74% (31/42) showed recurrence with the same pattern without distant disease. On the basis of these observations, they speculated on the possible role of local therapy (surgical consolidation or radiotherapy) after a maximum response to systemic chemotherapy.
So far, several retrospective studies have shown improved outcomes in patients with initially unresectable or regional node-positive bladder cancer following postchemotherapy surgery. Table 1 summarizes the outcomes of metastasectomy for locally advanced and/or nodal disease. Donat et al. [8] reported that, in 41 patients with locally advanced bladder cancer initially treated by MVAC chemotherapy, postchemotherapy surgery was completed in 24 patients. On pathological examination, no viable cell remained in 33% (8/24) of patients. Regarding the survival outcomes, of the 14 patients with clinical CR, eight underwent subsequent cystectomy, five refused surgery, one had unresectable tumor at surgery, and 50% (7/14) survived. On the contrary, of the 27 nonresponders, 16 underwent cystectomy, 11 did not due to unresectable tumor, and 7% (2/27) survived. In addition, of the five patients with clinical CR who refused postchemotherapy surgery, only one patient survived. Their observations indicated that surgical consolidation www.co-urology.com Regarding the resection of nonregional lymph node metastases, several researchers have reported promising outcomes [11] [12] [13] [14] [15] [16] . Sweeney et al. [11] reported the outcomes of their phase 2 study of a combined surgery and chemotherapy approach to sub-diaphragmatic lymph metastasis from bladder carcinoma in the absence of distant metastasis. A total of 11 patients with CR (n ¼ 7) or PR (n ¼ 4) after systemic chemotherapy were included. After postchemotherapy bilateral complete retroperitoneal lymph node dissection (seven underwent concurrent cystectomy), nine patients (82%, 9/11) had residual disease in the retroperitoneal nodes on pathological examination, and the 4-year diseasespecific and recurrence-free survival rates were 36 and 27%. Sub-analysis revealed that the number of viable tumors in less than two lymph nodes was correlated with prolonged disease-specific (P ¼ 0.006), and recurrence-free (P ¼ 0.01) survival. de Vries et al. [13] reported their aggressive approach to sub-diaphragmatic lymph node metastasis from bladder carcinoma in the absence of distant metastasis. After four cycles of cisplatin-based chemotherapy, 14 patients (CR ¼ 5, PR ¼ 9) underwent complete retroperitoneal lymph node dissection and cystectomy. On pathological examination, no residual disease was detected in 29% (4/14) of patients, and the 3 and 5-year disease-specific survival rates were 36 and 24%, respectively. Very recently, Necchi et al. [15 & ] also supported an aggressive surgical approach to this disease entity. Of 59 patients with sub-diaphragmatic, abdominal, or pelvic nodal disease and who showed at least stable disease after 4-6 cycles of a modified MVAC regimen (35 had metastasis at diagnosis, whereas 24 developed relapse after surgery), 28 underwent postchemotherapy consolidative surgery (study group, pelvic lymph node dissection: n ¼ 14, retroperitoneal lymph node dissection: n ¼ 11, both: n ¼ 3), whereas 31 did not (control group) due to either achieving CR after modified MVAC (n ¼ 9), undergoing consolidative chemotherapy with/ without radiation (n ¼ 14), a history of major complications after the previous surgery (n ¼ 4), or unknown reasons (n ¼ 4). On pathological examination, no viable cells remained in 29% (8/28) of patients of the study group. The median overall survival was 37 months in the study group, whereas it was 19 months in the control group (log-rank test, P ¼ 0.005). Postchemotherapy surgery remained significant in a multivariate model (hazard ratio 0.30, 95% CI 0.13-0.70, P ¼ 0.005).
RESECTION OF VISCERAL METASTASIS
As described above, since the first promising study by Cowles et al. [17] , visceral metastasectomy has been offered to selected patients. Table 2 summarizes the outcomes of metastasectomy for visceral organs [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . For example, Siefker-Radtke et al. www.co-urology.com Median OS 27 months from metastasectomy, 5-year OS 28% from metastasectomy [19] Abe et al. Miller et al. cycles of the CMV regimen were considered eligible for surgery.
Viable cells were confirmed in 83% (25/36) of the specimens. 3-year OS 82% for pathological CR group, 46% for surgical CR group, and 0% for unresectable group from the start of chemotherapy.
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Premetastasectomy chemotherapy using a platinum agent was performed in 4 patients.
Pathology was not described. Median OS 31.3 months after recurrence documented [24] Kim et al. Responses were not assessed.
Pathology was not described. 5-year OS 50% from metastasectomy [27] Han et al. Recently, several groups reported promising outcomes following surgical resection for pulmonary urothelial carcinoma metastasis [26] [27] [28] . Kanzaki et al. [26] reported outcomes whereby, in 18 patients undergoing pulmonary metastasectomy from urothelial carcinoma, the 3 and 5-year overall survival rates were 59.8 and 46.5% respectively. They also observed a 5-year overall survival rate of 85.7% in solitary metastatic patients and 20% in multiple metastatic patients. Matsuguma et al. [27] reviewed their experiences involving 32 patients undergoing pulmonary surgical resection. Of the 32 patients, 11 underwent video-assisted thoracic surgery (VATS). The 5-year overall survival rate was 50%, and a size smaller than 3 cm was associated with prolonged survival in a multivariate model. Kim et al. [25] also reported the outcomes in 30 patients with metastatic urothelial carcinoma treated by metastasectomy between 2000 and 2014. Resected sites were the lung (80%, 24/80), lymph nodes (10%, 3/30), liver (7%, 2/30), and bone (3%, 1/30). The median overall survival time was 30 months from the time of metastasectomy, with a 3-year survival rate of 41%. Multivariate analysis revealed that nonpulmonary metastasectomy was the only independent adverse factor of overall survival (hazard ratio 9.10, P ¼ 0.001). Subgroup analysis of the pulmonary resection group showed that patients with solitary lung metastasis had a significantly longer progression-free survival than those with two or more (68 vs. 7 months, respectively; P < 0.0019). Recent accumulations of data regarding pulmonary resection for metastatic urothelial carcinoma reflect recent progress in endoscopic surgery, namely VATS in lung surgery, which could motivate patients and physicians to face the challenge of surgical elimination, if metastasis can be minimum-invasively resected. Recently, the feasibility of and improved postoperative convalescence following laparoscopic liver resection of colorectal metastases has been reported [40, 41] . Although solitary liver metastasis is rare in metastatic urothelial carcinoma, laparoscopic surgery might become an alternative procedure. In the near future, T-cell checkpoint-targeting agents like programmed cell death protein 1 and programmed death-ligand 1 inhibitors may make marked progress to improve treatment outcomes for metastatic urothelial carcinoma patients [42] . Nevertheless, we consider that surgical consolidation will still remain in our armamentarium.
CONCLUSION
The role of metastasectomy in metastatic urothelial carcinoma has not yet been examined in a randomized setting. Each study group has offered surgical consolidation to metastatic urothelial carcinoma patients according to their own guidelines, and there are many things in common, such as a good response to systemic chemotherapy, limited disease, the feasibility of resection, and a favorable performance status. In terms of locally advanced and/or node-positive bladder cancer, further studies supported the benefit of surgical consolidation after a good response to systemic chemotherapy. Regarding metastasectomy for visceral metastasis, recent evidence suggested that lung metastases (ideally a small solitary lesion) would be a good indication. Careful patient selection is mandatory.
